merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safety and FDA approval</answer>
<question_number>2</question_number>
<answer>By providing FDA-approved drugs through a telehealth platform with direct delivery and competitive pricing</answer>
<question_number>3</question_number>
<answer>Lack of oversight and safety risks</answer>
<question_number>4</question_number>
<answer>To regain market share from compounded drugs despite self-competition</answer>
<question_number>5</question_number>
<answer>Allows compounding during shortages; removal justifies legal challenges</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Increased access for uninsured patients with potential health risks</answer>
<question_number>8</question_number>
<answer>May lead patients to perceive branded drugs as safer</answer>
<question_number>9</question_number>
<answer>FDA shortage listing</answer>
<question_number>10</question_number>
<answer>Lower pricing as a signal</answer>